Disclosed herein is article includes a polymer layer under an external force causing the polymer layer to be under a first compressive mechanical stress; and a lubricating liquid within the polymer layer, the lubricating liquid being at a concentration within the polymer layer such that the lubricating liquid forms a stable overlayer over the surface of the polymer layer when the polymer layer is under the external force and the lubricating liquid does not form the stable overlayer over the surface of the polymer layer when the polymer layer is not under compressive stress.
This disclosure provides a system for generating liquid motion using a first electrode, second electrode, reservoir including a liquid electrolyte, and magnet. The combination of electrochemical and magnetic fields results in liquid motion that can be used for a variety of purposes.
The present application is directed to methods and systems for using contact electrification as an energy supply to do useful chemistry. In accordance with one aspect, the disclosed method stores such energy in chemical forms (e.g., ionization of polymeric materials) and transports it to the point of use. This energy can either be released at high voltage by building up excess charge in a capacitor (to do plasma chemistry or chemical biology) or low voltage by processing the charge directly (to do electrochemistry or form useful products).
Quantum reservoir computation is provided. A first feature vector is determined from input data. A plurality of qubits is configured in an initial configuration according to the first feature vector, wherein a detuning, Rabi frequency, phase, and/or position of each of the plurality of qubits is determined by a respective one of the values of the first feature vector. The plurality of qubits is evolved for a first time. The plurality of qubits is measured to obtain first measurements after the first time. The plurality of qubits is returned to the initial configuration. The plurality of qubits is evolved for a second time. The plurality of qubits is measured to obtain second measurements after the second time. A second feature vector is determined from the first and second measurements. The second feature vector is provided to a decoder and a characteristic of the input data is obtained therefrom.
5.
CHIMERIC SMALL MOLECULES FOR LABELING PROTEINS WITH IMMUNOGENIC MOIETIES AND METHODS OF USE THEREOF
Chimeric small molecules comprising an immunogenic display moiety and methods of using the chimeric small molecules to label proteins with the immunogenic display moiety for MHC display on the surface of a cell or to label cell surface proteins with the immunogenic display moiety for display on the surface of a cell, thereby inducing an immune response.
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6.
SOFT ORGANIC SALTS FOR BAROCALORIC HEAT TRANSFER AND STORAGE
The invention provides methods, compositions, and systems for barocaloric applications such as cooling, heating, and energy storage using soft organic salts.
A method of transferring energy comprising: applying energy to a composition comprising a pressure transmitting medium in contact with a pressure sensitive material, wherein the composition is compressed; decompressing the composition to allow the pressure sensitive material to undergo an exothermic phase transition; and removing the energy from the composition; wherein the pressure sensitive material undergoes a reversible phase transition upon application of pressure.
C09K 5/06 - Materials undergoing a change of physical state when used the change of state being from liquid to solid or vice-versa
F25D 9/00 - Devices not associated with refrigerating machinery and not covered by groups ; Combinations of devices covered by two or more of the groups
F28D 20/02 - Heat storage plants or apparatus in general; Regenerative heat-exchange apparatus not covered by groups or using latent heat
The present document relates to covalent compounds and uses thereof, including methods of targeting or engaging one or more targets with a covalent compound. Also provided herein are methods of treating a disease using such a compound and methods of identifying one or more targets using such a compound.
C07C 233/11 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
9.
PRIME EDITING METHODS AND COMPOSITIONS FOR TREATING TRIPLET REPEAT DISORDERS
HTTFXNFXN genes. Complexes, compositions, and systems comprising a prime editor and any of the pegRNAs disclosed herein are also provided by the present disclosure. The present disclosure further provides polynucleotides, vectors, AAVs, cells, compositions, and kits. Methods of treating Huntington' s disease and Friedreich's ataxia, as well as uses of the compositions, pegRNAs, and systems described herein, are also provided herein.
The technology described herein is directed to stromal-free methods of T cell differentiation using a soluble Notch ligand. Also described herein are soluble Notch oligomer complexes and compositions thereof, and methods for making the same. Further described herein are immune cells differentiated using stromal -free methods and compositions comprising such immune cells. In some embodiments, the immune cells can be genetically modified. In some embodiments, the immune cells or compositions comprising said immune cells can be administered to a patient as a cellular replacement therapy to treat a condition.
The present disclosure relates to pharmaceutical compositions comprising engineered macrophages and methods of use thereof. In some aspects, the present disclosure relates to engineered macrophages derived from pluripotent stem cells. In some embodiments, the stem cell genome is edited to knock-out (e g., SIRPa) and/or knock-in (e g., CAR) genes of interest prior to differentiation into macrophages. In some embodiments, engineered macrophages lack a SIRPa receptor. In some embodiments, the engineered macrophages express chimeric antigen receptors that induce and/or enhance phagocytosis. Alternatively, or additionally, in some embodiments, macrophages are engineered with combinatorial antigen-sensing circuits to improve tumor recognition and phagocytosis. Other aspects of the disclosure relate to methods of treating cancer in a subject and/or methods of enhancing cancer cell phagocytosis.
The technology described herein is directed to adjuvants comprising ionic liquids, as well as compositions and methods utilizing or comprising such adjuvants.
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
14.
BASE EDITING METHODS AND COMPOSITIONS FOR TREATING TRIPLET REPEAT DISORDERS
The present disclosure provides compositions and methods useful in the treatment of trinucleotide repeat disorders, including Huntington's disease and Friedreich's ataxia. The present disclosure also provides gRNAs designed to target the HTT or FXN genes. Complexes comprising a base editor and any of the gRNAs disclosed herein are also provided by the present disclosure. The present disclosure further provides polynucleotides, vectors, cells, compositions, and kits. Methods of treating Huntington's disease and Friedreich's ataxia are also provided herein.
Systems and methods, and associated compositions, for producing large libraries of nucleic acids are generally described. The methods provided herein may be used to produce libraries that include mutations that are unlikely in conventional library generation techniques, and may facilitate the production of large libraries with reduced processing demands.
16.
SYSTEMS AND METHODS FOR SCREENING OF LARGE GENE LIBRARIES
Library screening is an important analytic tool for identifying functional nucleic acids or proteins. In some aspects, droplet-based systems and methods for library screening are provided. The systems and methods may include steps of sorting droplets based on activity, amplifying nucleic acids of "activity droplets" having high activity, and separating nucleic acids from the activity droplets into new droplets. The steps may be iterated, such that activity droplets from successive iterations tend to include fewer nucleic acids. Such approaches may facilitate identification of active nucleic acids, or of nucleic acids encoding active proteins.
A particle alpha radiation sampler includes a scintillation cell, a Geiger counter for measuring the incidence of particle alpha radiation on the scintillation cell, a vessel defining a chamber, at least one inertial impactor, a filter, and a vacuum pump. The scintillation cell is configured to receive alpha radiation passing through air in the chamber from particulate matter collected on the filter. The inertial impactor is configured to allow passage of particles only at or below an established size threshold into the chamber. The filter is configured to collect particulate matter from the air in the chamber drawn through the inertial impactor. Finally, the vacuum pump is configured to draw air flow through the filter from the chamber and to draw air flow through the inertial impactor into the chamber.
The present disclosure provides compositions, methods, kits and uses for regulating blood-Central Nervous System (blood-CNS) barrier permeability (e.g., increasing or decreasing blood-CNS barrier permeability) by regulating signaling between endothelial cell derived Cede 141 and Pacsin2 expressed in CNS endothelial cells.
Provided herein are methods of treating cancer in a subject, the method comprising administering to the subject an agent that increases or stabilizes the activity or expression of PIEZO 1.
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Provided herein are compounds that promote targeted degradation of IKZF1, IKZF2, GSPT1, and/or CKla, proteins whose activities are implicated in the pathology of certain cancers (e.g., acute myeloid leukemia). Also provided are pharmaceutical compositions comprising the compounds. Also provided are methods of treating cancer, and methods of promoting the degradation of IKZF1, IKZF2, GSPT1, and/or CKla in a subject or biologcial sample by administering a compound or composition described herein.
The technology described here is directed to a system and method of determining a bolus insulin dose for a person with diabetes to address prolonged hyperglycemia. A bolus insulin dose for the person is output from a jointly weighted zone model predictive control. The algorithm has a cost function that minimizes predicted glucose deviation from the upper zone weighted by a joint function of predicted glucose rate-of-change (ROC) and insulin-on-board (IOB). The asymmetric weighting gradually increases when glucose ROC and IOB were jointly low, independent of glucose magnitude, to limit hyperglycemia while aggressively reduces the weight for negative glucose ROC to avoid hypoglycemia.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
Dielectric elastomer actuators and methods of manufacturing thereof are generally described. The methods of manufacturing dielectric elastomer actuators comprise two independent steps: (1) depositing a conductive material on a plurality of portions of one or more carrier substrates to form a plurality of electrodes; and (2) transferring the plurality of electrodes to a plurality of elastomer layers to form dielectric elastomer actuators.
H10N 30/05 - Manufacture of multilayered piezoelectric or electrostrictive devices, or parts thereof, e.g. by stacking piezoelectric bodies and electrodes
H10N 30/20 - Piezoelectric or electrostrictive devices with electrical input and mechanical output, e.g. functioning as actuators or vibrators
H10N 30/50 - Piezoelectric or electrostrictive devices having a stacked or multilayer structure
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
H01B 1/20 - Conductive material dispersed in non-conductive organic material
24.
PERFUSABLE 3D TUBULE-ON-CHIP MODEL DERIVED FROM KIDNEY ORGANOIDS WITH IMPROVED DRUG UPTAKE
Described herein are perfusable 3D tubule-on-chip models comprising at least one tubule consisting of one patent lumen circumscribed by organoid- derived cells, and a multifluidic platform comprising at least one individually addressable chip. The models may further include an unseeded tubule, where the seeded tubule and the unseeded tubule are co-localized on the chip, and wherein the tubule and the unseeded tubule are embedded within a gelatin-fibrin extracellular matrix (ECM). Also, described here are methods of producing the described perfusable 3D tubule-on-chip models, and uses of the same.
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
Aspects of the disclosure relate to Botulinum toxin X (BoNT X) protein variants. The variants provided herein have been evolved to cleave GTP cyclohydrolase 1 (GCH1). Some of the variants provided herein were evolved from a procaspase- 1 cleaving polypeptide. Further aspects of the disclosure relate to nucleic acids encoding the GCH1 cleaving polypeptides described herein and expression vectors comprising the nucleic acids, as well as host cells and fusion proteins comprising the GCH1 cleaving polypeptides described herein, and kits comprising the GCH1 polypeptides, fusion proteins, nucleic acids, expression vectors, or host cells described herein. Further aspects of the disclosure relate to methods of producing BoNT X variants and methods of using the BoNT X protein variants, for example, to reduce pain.
The present invention provides methods and compositions for treating cancers, as well as methods for increasing an immune response against a tumor, in a subject in need thereof by decreasing the expression and/or activity of Stub1 in an immune cell of the subject.
Genetic circuits that control transgene expression in response to pre-defined transcriptional cues would enable the development of smart therapeutics. The present disclosure relates to engineered programmable single-transcript RNA sensors in which adenosine deaminases acting on RNA (ADARs) autocatalytically convert trigger hybridization into a translational output. This system amplifies the signal from editing by endogenous ADAR through a positive feedback loop. Amplification is mediated by the expression of a hyperactive, minimal ADAR variant and its recruitment to the edit site via an orthogonal RNA targeting mechanism. This topology confers high dynamic range, low background, minimal off-target effects, and a small genetic footprint. The circuits and systems disclosed herein leverage an ability to detect single nucleotide polymorphisms and modulate translation in response to endogenous transcript levels in mammalian cells.
The present invention relates to systems, compositions, and methods for altering nucleic acids, such as at a single position (e.g., A/T to G/C or G/C to A/T; in a gene with disease causing SNP). In particular, the present invention relates to engineered CRISPR/Cas systems comprising: a first Cas protein (e.g., Cas5-8 or Cas11) which is optionally tethered or fused to an effector protein selected from: i) an adenine deaminase, ii) a uracil glycosylase inhibitor, or iii) an APOBEC protein; and at least one guide RNA (gRNA) configured to hybridize to a portion of a target nucleic acid sequence. In certain embodiments, the systems further comprise a second Cas protein selected from: i) Cas3, ii) a helicase-deficient Cas3; or iii) a single-strand nicking Cas endonucleases (e.g., Cas9 Nickase H840A Protein).
Systems and methods for monitoring an international normalized ratio (INR) of a patient are disclosed. In some embodiments, INR data associated with the patient is received from an INR level measurement device. In some embodiments, a warfarin dosage recommendation is received, and the warfarin dosage recommendation is based on the INR data. In some embodiments, one or more user interfaces are presented on a display, and the one or more user interfaces comprise a user interface element indicating the warfarin dosage recommendation.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
30.
MODE DIVISION MULTIPLEXING USING COMBINED DEGENERATE MODES
An optical communication system can include a multiplexer/demultiplexer. The multiplexer/demultiplexer can transfer a first optical data signal between a first single-mode fiber and a first propagation mode of a few-mode fiber. The first propagation mode can have a first effective refractive index. The multiplexer/demultiplexer can transfer a second optical data signal between a second single-mode fiber and a combination of a second propagation mode of the few-mode fiber and a third propagation mode of the few-mode fiber. The second propagation mode and the third propagation mode can have a same effective refractive index that differs from the first effective refractive index. During propagation within the few-mode fiber, the second optical data signal can couple bidirectionally between the second propagation mode and the third propagation mode, while being substantially isolated from the first optical data signal in the first propagation mode.
G02B 6/28 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals
B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
31.
DEVICE, METHODS, AND SYSTEMS FOR REGENERATIVE BAROCALORIC HEAT TRANSFER
F03G 7/06 - Mechanical-power-producing mechanisms, not otherwise provided for or using energy sources not otherwise provided for using expansion or contraction of bodies due to heating, cooling, moistening, drying, or the like
F28D 17/04 - Distributing arrangements for the heat-exchange media
F28F 23/00 - Features relating to the use of intermediate heat-exchange materials, e.g. selection of compositions
F25B 23/00 - Machines, plants or systems, with a single mode of operation not covered by groups , e.g. using selective radiation effect
The present disclosure generally relates to evolved cytidine deaminases derived from cytidine deaminases, and methods of editing DNA using the same. In some aspects, the disclosure describes the directed evolution of a TadA-derived adenosine deaminase (TadA- CD) to perform cytidine deamination. In some embodiments, the TadA-CDs comprise a plurality of mutations compared to the parent TadA variant. In some embodiments, the TadA-CD is fused to a programmable DNA binding protein. Other aspects of the disclosure generally relate to a cytosine base editor (CBE) comprising a programmable DNA binding protein and the TadA-CD. In some embodiments, the disclosed cytosine base editor has improved efficiencies of conversion and reduced off-target editing frequencies compared to naturally-occurring CBEs. Also provided are polynucleotides, vectors, and kits useful for the generation and delivery of the CBEs. Cells containing such vectors and CBEs are also provided. Further provided are methods of treatment comprising administering the CBEs.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
33.
STEREOLITHOGRAPHY ADDITIVE MANUFACTURING OF MAGNETICALLY ALIGNED LIQUID CRYSTAL ELASTOMERS
A method of forming a three-dimensional structure includes forming a layer of resin comprising liquid crystal oligomers and a photoinitiator, applying a magnetic field to the formed layer in a predefined alignment direction for substantially aligning the liquid crystal oligomers in a first orientation; and exposing the formed layer to radiation for curing a first portion of the layer during application of the magnetic field thereby resulting in the first portion having liquid crystal elastomers substantially aligned in the first orientation. The method includes applying a second magnetic field to the formed layer in a predefined second alignment direction for substantially aligning uncured liquid crystal oligomers in a second orientation, and exposing the layer to radiation for curing a second portion of the layer during application of the second magnetic field thereby resulting in the second portion having liquid crystal elastomers substantially aligned in the second orientation.
B29C 64/188 - Processes of additive manufacturing involving additional operations performed on the added layers, e.g. smoothing, grinding or thickness control
B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
Described herein are hematopoietic cell-specific targeting moieties and compositions including the hematopoietic cell specific targeting motifs. Also described herein are uses of the hematopoietic cell-specific targeting motifs and compositions including the hematopoietic cell specific targeting moieties. In some embodiments, the hematopoietic cell-specific targeting moieties and compositions including the hematopoietic cell specific targeting moieties can be used to direct delivery of a cargo to a hematopoietic cell.
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present disclosure relates to a method of inducing cellular rejuvenation and/or regeneration of a cell or tissue comprising contacting the cell with an effective amount of a protein or nucleic acid encoding a protein that induces cellular rejuvenation and/or regeneration of a cell or tissue. The present disclosure describes cell or tissue prepared according to methods described herein. The present disclosure also provides for methods of treating patients using cell or tissue generated by the methods described herein. The present disclosure also provides methods and systems for identifying a perturbant capable of changing a cell's state, function, and predicted age from an old reference state to a younger altered state.
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
The present disclosure provides methods of use of a particular GABA-A modulator compound, including in particular patient populations and/or for particular indications (e.g., diseases, disorders, or conditions).
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 9/113 - Multiple emulsions, e.g. oil-in-water-in-oil
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A photophoretically levitating macroscopic structure includes a photophoretically active structure (PAS), a PAS support framework, and a device superstructure. The photophoretically active structure includes at least one top sheet and at least one bottom sheet. The bottom sheet has greater solar-radiation absorptivity than the top surface, and each sheet defines a pattern of holes through which gas can flow. The sheets are separated by a gap that defines an open volume extending across a plurality of holes in each sheet. The photophoretically active structure is mounted in or on the PAS support framework. The device superstructure is mounted to and spans the PAS support framework to increase the rigidity of the photophoretically levitating macroscopic structure.
e.g., in situin situ, thereby providing multiple landing pads for labeled probes. The methods are well-suited to performance in multiplex, thereby permitting the sensitive detection of multiple targets in a single assay. These methods and compositions can be applied to, among other things, imaging, flow cytometry, CyTOF, and immunoblotting, providing additional tools for research and diagnostic purposes.
The methods, compositions and kits described herein provide signal amplification approaches for the detection of target biomolecules that significantly increase the sensitivity of detection using target-binding ligand molecules. The methods include cyclic addition of nucleic acid repeats to, e.g., target-binding molecules, thereby providing multiple landing pads for labeled probes. The methods are well-suited to performance in multiplex, thereby permitting the sensitive detection of multiple targets in a single assay. These methods and compositions can be applied to, among other things, imaging, flow cytometry, and mass cytometry/CyTOF, providing additional tools for research and diagnostic purposes.
A system is provided for embedding visualizations in a video stream of an athletic game based on a text relating thereto. The video stream may include a temporal sequence of video frames. The system may include a processor, a frame buffer for storing video stream comprising a temporal sequence of video frames. The system may also include an analysis module, executable by the processor, for analyzing the text to detect references therein to visualizable entities. The system may also include a mapping module, executable by the processor, for mapping the detected visualizable entities to visualizations. The system may also include an embedding module, executable by the processor, for embedding the generated visualizations in the video stream.
Mucispirillum M. schaedleriMucispirillum M. schaedleriM. schaedleri, XCL1 polypeptide, NKTs, and/or CD103+ cDC1s, and alteration or stratification of treatment accordingly.
Aspects of the disclosure relate to compositions and methods for targeted protein degradation. In some embodiments, the disclosure relates to methods of evolving protein degrons to interact with certain small molecule inducers (e.g., VS-777, PT- 179, or PK-1016). In some embodiments, the disclosure relates to compositions (e.g., peptides, nucleic acids encoding the protein degrons, etc.) used for targeted protein degradation. In some embodiments, the disclosure relates to methods of degrading a target polypeptide in a cell.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
ROS signal upregulates surface CALR and promotes macrophage-HSC interactions, safeguarding the development of stem cells that are stressed or damaged. Described herein are methods of controlling hematopoiesis, e.g., reducing hematopoiesis and/or improving the quality control mechanisms of hematopoiesis, relating to the use or administration of at least one CALR agonist.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
46.
BUILDING AS AN INSTRUMENTATION FOR DATA-DRIVEN BUILDING OPERATION
There is provided a system for environmental control in a building. The system includes a plurality of sensors including operational sensors and data gathering sensors, and a plurality of actuators. The system also includes a rule-based server and a data-driven server coupled to the plurality of sensors and the plurality of actuators. The rule-based server receives operation signals from the operational sensors, and control operation of the plurality of actuators according to one or more rules based on the operation signals. The data-driven server receives or monitors data signals from the data-gathering sensors and the operation signals from the operational sensors, trains and/or applies data-driven models to the data signals and the operation signals to predict performance changes in the building due to a command. In accordance with a determination that the performance changes meet a predetermined criteria, the data-driven server controls operations of the plurality of actuators according to the command.
F24F 11/74 - Control systems characterised by their outputs; Constructional details thereof for controlling the supply of treated air, e.g. its pressure for controlling air flow rate or air velocity
F24F 11/84 - Control systems characterised by their outputs; Constructional details thereof for controlling the temperature of the supplied air by controlling the supply of heat-exchange fluids to heat-exchangers using valves
The present invention relates to an optical lens for augmented visual perception of a scene, the optical lens comprising a bandpass filter or a blurring filter, so as to lower contrast and high spatial frequencies of the scene.
Provided herein arc compounds of Formula (I- A), (I-B), or (I-C), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically enriched forms, prodrugs, or mixtures thereof, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing diseases and/or conditions (e.g., neurological disease (e.g., Alzheimer's disease, multiple sclerosis, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis), metabolic disorder (e.g., obesity, diabetes, X-linked adrenoleukodystrophy (X-ALD)), proliferative disease (e.g., cancers), hepatic disease (e.g., liver cirrhosis), conditions associated with autophagy (e.g., neurodegenerative disease, infection, cancer, conditions associated with aging, heart disease), conditions associated with aging, conditions associated with modulating the mPTP, cardiovascular conditions (e.g., ischemia-reperfusion injury), stroke, heart attack, conditions associated with oxidative stress, mitochondrial diseases, or other diseases associated with cyclophilins) in a subject, as well as for reducing oxidative stress. Provided are methods of inhibiting a cyclophilin in a subject, cell, tissue, and/or biological sample. Provided are methods of selectively inhibiting a cyclophilin (e.g., CypD, CypE) in a subject, cell, tissue, and/or biological sample.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
Described herein are vaginal lactobacilli strains that actively modulate mucosal immunity, and compounds produced by these bacteria that exhibit anti-inflammatory activity.
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
The present disclosure provides Cas protein variants comprising one or more amino acid substitutions relative to wild-type Casl4al. Fusion proteins comprising the Cas protein variants described herein are also provided by the present disclosure. Further provided herein are methods for modifying a target nucleic acid using the Cas proteins and fusion proteins provided herein. The present disclosure also provides guide RNAs, complexes, polynucleotides, systems, cells, kits, and pharmaceutical compositions.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
The present disclosure shows that by combining pH-responsive bridging chitosan polymer chains and a tough hydrogel dissipative matrix one can achieve unprecedented ultra- tough adhesion to tissues (>2000J/m2) in 5-10mins without covalent bond formation. The strong non-covalent adhesion was shown to be stable under physiologically relevant conditions and strongly influenced by chitosan molecular weight, molecular weight of polymers in the matrix, and pH. The adhesion mechanism relies primarily on the topological entanglement between the chitosan chains and the permeable adherends. The present disclosure also discloses dry polymer films to generate instant adhesion between hydrogel-hydrogel and hydrogel-elastomer surfaces. Unprecedented adhesive energies (>3000J/m2) between alginate-polyacrylamide tough hydrogels were achieved instantaneously using an intermediate chitosan film, governed by pH change, H-bonding, and bridging polymer entanglement. Furthermore, this strategy also generates instant strong adhesion between acrylic elastomers and tough hydrogels with adhesion energy as high as 4000J/m2.
Provided herein are Anorogenic nucleosides (e.g., Anorogenic nucleoside triphosphates (NTPs), e.g., Anorogenic reversible terminator nucleoside triphosphates) which can be used in the synthesis of Anorogenic oligonucleotides (e.g., Anorogenic DNA or RNA oligonucleotides, such as Anorogenic RNA aptamers). The Anorogenic oligonucleotides (e.g., Anorogenic DNA or RNA oligonucleotides, such as, Anorogenic RNA aptamers) can be used as Anorogenic probes to detect targets (e.g., antigens, biomarkers).
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
The invention relates to non-naturally occurring in vitro-derived peripheral endothelial cells and brain endothelial cells. It further discloses methods of making said in vitro-derived peripheral endothelial cells and brain endothelial cells by differentiating human pluripotent cells into Endothelial Cells (ECs) by mesodermal commitment followed by expansion and isolation of ECs. The invention also relates to methods of using the cells or cell populations in methods of cell therapy.
The present disclosure provides zinc finger domain-containing proteins comprising optimized a-, P-, and linker motifs, and fusion proteins comprising said zinc finger domain-containing proteins fused to an effector domain. The present disclosure also provides double-stranded DNA deaminase A (DddA) variants and fusion proteins comprising said DddA variants fused to a programmable DNA binding protein (e.g., any of the zinc finger domain-containing proteins disclosed herein, a TALE protein, or a CRISPR/Cas9 protein). Methods for editing DNA (including genomic DNA and mitochondrial DNA) using the fusion proteins described herein are also provided by the present disclosure. The present disclosure further provides polynucleotides, vectors, cells, kits, and pharmaceutical compositions comprising the zinc finger domain-containing proteins, DddA variants, and fusion proteins described herein.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
ÖSTERREICHISCHE AKADEMIE DER WISSENSCHAFTEN (Austria)
QUERA COMPUTING INCORPORATED (USA)
Inventor
Lukin, Mikhail, D.
Liu, Jinguo
Nguyen, Minh-Thi
Pichler, Hannes
Wang, Shengtao
Wurtz, Jonathan
Abstract
Quantum optimization with Rydberg atom arrays is provided. In particular, methods are provided for solving combinatorial graph optimization problems, constraint satisfaction problems, maximum independent set problems, algebraic problems, and factoring.
The present invention relates to novel biomarkers and combinations thereof for cell type-specific and/or organ-specific extracellular vesicles, in particular, brain-specific and/or neuron-specific extracellular vesicles. The present invention also provides methods for isolation and/or enrichment of cell type-specific and/or organ-specific extracellular vesicles, methods for identification of extracellular vesicles derived from a cell, and methods for diagnosing or prognosing a disorder, e.g., a neurodegenerative disorder, using the cell type specific and/or organ-specific extracellular vesicles. Compositions in the form of kits of reagents for detecting the cell type-specific and/or organ-specific extracellular vesicles are also provided.
The invention involves assays, diagnostics, kits, and assay components for determining levels of glycated CD59 in the assessment of gestational diabetes mellitus and/or related disorders and/or conditions. Further, wherein an antibody comprising: a light chain variable domain comprising CDRs in a light chain sequence; and a heavy chain variable domain comprising CDRs in a heavy chain sequence.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
58.
METHODS AND COMPOSITIONS RELATING TO TREATMENT OF CNS DISEASES
Described herein are methods relating to the treatment of certain diseases with an agonist of Mfsd2A, and the treatment of certain other diseases with an inhibitor of Mfsd2A.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Compositions and methods for treating a blood disorder in a subject comprising delivering a nucleic acid molecule including a nucleotide sequence encoding two to six guide RNAs (gRNAs) into a hematopoietic stem cell (HSC), a hematopoietic progenitor cell (HPC), or a population of hematopoietic stem and progenitor cells (HSPCs) are described.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C07K 14/74 - Major histocompatibility complex (MHC)
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
61.
WEARABLE SYSTEM FOR THERAPEUTIC AFFERENT NERVE ELECTRICAL STIMULATION
A device and system are disclosed for providing stimulation therapy. The device inlcudes a substrate with a bottom surface and a top surface opposite from the bottom surface. The bottom surface has an adhesive configured to adhere the substrate to skin of a user. The device further includes a first microneedle array electrode on the bottom surface of the substrate. The device further inlcudes a second electrode on the bottom surface of the substrate, spaced apart from the first microneedle array electrode. The device further includes a power receiver circuit attached to the substrate and configured to wirelessly receive power. The power receiver circuit is electrically connected to the first microneedle array electrode and the second electrode.
Viscoelastic hydrogel microparticles are used for repair of tissue defects and injuries or filling and occlusion of anatomical structures. These are administered as a microparticle suspension using a catheter, syringe, steerable catheter tip, or comparable technology into the site, where they can be further stabilized by crosslinking or sealing, or through incorporation of a support or encapsulating structure. Materials and methods for solidifying, stabilizing and sealing these materials can be used that are also biocompatible and easily deployed with catheters in the body. The micron sized interstitial spacing provides a scaffold for ingrowth and migration of cells into the gel matrices.
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS ( CIC BIOGUNE) (Spain)
UNIVERSITY OF LUXEMBOURG (Luxembourg)
Inventor
Plesa, Alexandru
Jung, Sascha
Church, George, M.
Mesa, Antonio Del Sol
Wang, Helen
Shadpour, Michael
Abstract
The disclosure relates to a method of inducing cellular rejuvenation of a cell comprising contacting the cell with an effective amount of a SRSF1, SLC2A13, RNASEL, WDTC1, and/or NPM1 protein or a nucleic acid encoding the SRSF1, SLC2A13, RNASEL, WDTC1, and/or NPM1 protein. The disclosure also relates to a method of inducing cellular rejuvenation of a cell comprising contacting the cell with an effective amount of an inhibitor of KAT7, ESR1, MAPK7, KDM6A, and/or CTNNB1 protein expression or expression of a nucleic acid encoding a KAT7, ESR1, MAPK7, KDM6A, and/or CTNNB1 protein.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
64.
AAV VECTORS ENCODING BASE EDITORS AND USES THEREOF
Nucleic acid molecules, compositions, recombinant AAV (rAAV) particles, kits, and methods are described herein for delivering a base editor (or "nucleobase editor") to cells, e.g., via AAV vectors. In particular, the disclosure provides compositions, methods, and uses for delivery of adenine base editors and cytosine base editors in a single AAV vector (or genome). Further described herein are improved AAV vectors containing size-minimized regulatory components that enable, e.g., the packaging of base editors. Provided herein are methods and compositions for delivering base editor proteins to a cell or tissue in a single recombinant AAV (rAAV) vector. Contemplated herein are improved methods and compositions for delivering these base editors in vivo, in a single rAAV particle. Further provided herein are base editors and compositions and cells comprising these base editors.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The present disclosure is generally directed to systems and methods for retrieving cells from a continuous culture microfluidic device. In some aspects, a system that allows for selective extraction of one or more cells of interest from an arbitrary population of cells using a high-throughput negative cell selection technique is disclosed herein. For example, the system may comprise a microfluidic device comprising a plurality of cell growth trenches configured to contain cells and a patterned light source capable of selectively killing unwanted cells contained within the device. Coupled with time-lapse imaging, one or more cells of interest within the device may, in some aspects, be identified and extracted with a relatively high extraction efficiency, e.g., at least 99.9% of cells of interest may be extracted from the plurality of cells. In addition, some aspects of the disclosure are directed to methods for using such a system.
Provided herein are methods and compositions for differentiating induced pluripotent stem cells into microglia-like cells by overexpressing transcription factors such as SPI1, CEBPA, FLU, MEF2C, CEBPB, and/or IRF8.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Provided are compounds useful for the treatment and prevention of infectious diseases. The compound structures are lincosamide analogs modified at the aminooctose (northern) and amino acid (southern) regions. Also provided are methods for preparing the lincosamide compounds, pharmaceutical compositions comprising the lincosamide compounds, and methods of treating infectious diseases using the disclosed lincosamide compounds.
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
C07D 411/02 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
C07H 19/01 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof sharing oxygen
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Disclosed herein are various improvements in prime editing (PE) relating to the optimization of various aspects and parameters of PE, including optimizing the conducting of PE and twin prime editing ("twinPE") experiments, as well as optimizing the design of pegRNAs and second-strand nicking guide RNAs.
Provided are isolated enhancer element sequences that regulate and restrict expression of a transgene, such as a therapeutic gene, to certain neuronal cell types and/or populations in the brain and CNS. Therapeutic virus vectors containing the cloned enhancer element sequences, particularly, recombinant adeno-associated virus (rAAV) vectors, and a transgene are described. The rAAV vectors, compositions and methods are useful for treating subjects afflicted with neuropsychiatric and neuropathological diseases, disorders and conditions and symptoms thereof. The vectors can be used to restore normal cellular function, e.g., by restoring expression of certain genes to the appropriate interneuron or neuron target cell populations, to address the root cause of the disease, e.g., by restoring the excitation-inhibition balance in the neuronal cell or cell population.
Addressable actuator and arrays thereof are described. Actuators may be dielectric elastomer actuators (DBAs). An addressable actuator may include a compliant substrate, with an optical receiver integrated with a first region of the compliant substrate and an actuator integrated with a second region of the compliant substrate, with the optical receiver coupled to the actuator. The optical receivers may comprise percolating networks of semiconductor materials, such as photoconductive channels of zinc oxide nanowires, which may be embedded in a compliant substate, or one or more compliant layers (which may be formed on a substrate). Compliant substrates or layers may include complaint materials such as an elastomer. An actuator array may comprise multiple of the actuators, with each actuator being independently optically addressable. A system may include light emitting devices optically coupled to respective optical receivers to control actuation of the actuators using light.
H01B 1/08 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances oxides
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
72.
COMPOSITIONS AND METHODS FOR LOCALIZED DELIVERY OF CYTOKINES FOR ADOPTIVE CELL THERAPY
Disclosed herein are compositions and methods for metabolically labeling cells using click chemistry reagents. The compositions and methods disclosed herein provide a specific and efficient means of localizing desired agents, such as anti-tumor cytokines, to a variety of cell types for adoptive cell therapy.
ex vivoe.ge.ge.ge.g.e.ge.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
74.
INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS
Provided herein are compounds, such as compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, and compositions, methods, uses, and kits thereof. The compounds provided herein are DDR1, DDR2, or p38 MAPK (e.g., p38-alpha) inhibitors and are therefore useful for the treatment and/or prevention of various diseases and conditions (e.g., inflammatory diseases, joint diseases, proliferative diseases, fibrosis, or pain).
A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
C07C 309/29 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
75.
CAS9 VARIANTS HAVING NON-CANONICAL PAM SPECIFICITIES AND USES THEREOF
The present disclosure provides Cas9 variants, and base editors comprising these variants, that recognize non-canonical protospacer adjacent motifs (PAMs) and have less restrictive PAM requirements for editing. The present disclosure provides Cas9 protein variants comprising one or more amino acid substitutions relative to wild-type Nme2Cas9. Fusion proteins comprising the Cas protein variants described herein are also provided by the present disclosure. Further provided herein are methods for editing a target nucleic acid using the Cas variants and fusion proteins provided herein. The present disclosure also provides guide RNAs, complexes, polynucleotides, cells, kits, and pharmaceutical compositions. Further described herein are phage-assisted continuous evolution (PACE) systems, vectors, methods, and devices.
Disclosed herein are optimized methods of high efficiency purification of adeno- associated virus (AAV) particles, comprising a step of binding one or more AAV particles with a volume of chromatography resin medium comprising at least one ligand possessing a pan-AAV affinity. The optimized methods are capable of providing purified AAV particles comprising a wide diversity of AAV serotypes without the need to further optimize for a given AAV serotype.
C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The technology described herein is directed to immune modulatory agents and methods of use. In some aspects, described herein are agents that modulate IL-17a/IL-17 receptor- induced signalling and/or IL-17f/IL-17 receptor-induced signalling and associated methods of use thereof. In some aspects, described herein are agents that modulate TNF-α/TNF receptor signalling and associated methods of use thereof.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
The present invention discloses compositions and methods for modulating the immune system in a subject. The compositions of the present invention comprise a porous scaffold biomaterial comprising active agent. The method of the present invention comprises administering to a subject a scaffold composition comprising active agent, thereby modulating the immune system in a subject.
A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
79.
METHODS AND COMPOSITIONS FOR PRODUCING GRANULOSA-LIKE CELLS
Provided herein are methods and compositions for differentiating induced pluripotent stem cells into granulosa-like cells by overexpressing transcription factors such as NR5A1 and a RUNX family protein (e.g., RUNX1 and/or RUNX2).
Provided herein are methods and compositions for differentiating induced pluripotent stem cells into primordial germ cell-like cells by overexpressing transcription factors such as DLX5, HHEX, and/or FIGLA.
Provided herein are methods and compositions for differentiating induced pluripotent stem cells into oogonia-like cells by overexpressing transcription factors such as ZNF281, LHX8, and/or SOHLH1.
A device is provided for performing an electrical assessment in a biological environment. The device includes a substrate having an exposed surface having holes. At least one of the holes includes surfaces coated with a conductive material that is in electrical contact with an electrode. The device also includes circuitry controllable to apply a stimulus to the conductive material of the hole by applying the stimulus to the electrode in electrical contact with the hole. The hole may be disposed in a well structure that includes a wall surrounding the hole. The well structure may have a dimension such that a cell of interest in the biological environment is able to cover an entirety of a rim of the wall of the well structure. The wall of the well structure may surround one or more of the holes, which may be in electrical contact with a same electrode.
A method of microwave-assisted or microwave-activated thermal curing includes forming a colloidal suspension into a predetermined shape, where the colloidal suspension comprises an aqueous solution including water, a crosslinkable polymer dissolved in the water, and inorganic particles dispersed in the aqueous solution at a concentration of at least about 10 vol.%. The colloidal suspension is then exposed to microwave irradiation for about two minutes or less, such that the crosslinkable polymer undergoes thermal curing, and a polymer composite having the predetermined shape is formed. The polymer composite comprises a crosslinked polymer matrix with the inorganic particles dispersed therein. The polymer composite may serve as a precursor for a densified or sintered inorganic (e.g., ceramic) part.
Various aspects of the instant disclosure relate to a nanostructured agrichemical delivery vehicle. The vehicle has a core-shell structure. The core includes a first polymeric material. The shell at least partially encases the core. The shell includes a second polymeric material. The core, the shell, or both include an agrichemical component distributed about the first polymeric material, the second polymeric material, or both. The release of the agrichemical component from the core, the shell or both is triggered by exposure to at least one of a predetermined enzyme, a predetermined pH, a predetermined biotic secretion, a predetermined temperature, a predetermined moisture content, a predetermined light source.
The present disclosure provides arrestin domain-containing protein 1 (ARRDC1)- mediated microvesicles (ARMMs) modified with Nipah virus (NiV) glycoproteins fused to antibodies or antigen-binding fragments and NiV fusion proteins, and variants thereof. The ARMMs of the present disclosure may be targeted to particular cell types and used to deliver agents (e.g., therapeutic agents) to target cells. Microvesicle-producing cells are also provided by the present disclosure. The present disclosure also provides methods of delivering molecules to target cells using the ARMMs described herein, and methods of treating a patient using any of the ARMMs or microvesicle-producing cells provided herein. Kits comprising any of the ARMMs or microvesicle-producing cells described herein are also provided by the present disclosure.
In one aspect, a specimen holder includes a first end configured to attach to a cooling device and a second end configured to be inserted into a microscope; a section with a sample tip at the second end; an interface between the first end configured to attach to the cooling device and the section with the sample tip; and an internal thermal connection section configured to be in thermal contact with a cold finger of the cooling device when the specimen holder is attached to the cooling device and extending through the section with the sample tip to the sample tip.
A suturable cuff for integrating a tissue construct in vivo with a host organ or vasculature comprises a hollow body having an anastomotic end, an anchoring end, and one or more lumens, where each lumen extends through the hollow body from a proximal opening at the anastomotic end to a distal opening at the anchoring end. The anastomotic end is configured for integration with one or more body vessels, and the anchoring end includes one or more anchoring features for connection with the tissue construct.
90.
IMPROVED METHODS FOR NEOPLASIA DETECTION FROM CELL FREE DNA
The invention features compositions and methods that are useful for determining the fraction of tumor-derived DNA (tumor fraction; TF) in cell free DNA (cfDNA). The methods involve calculating the fraction of tumor-derived DNA in the cfDNA using a combination of copy number alteration data and fragment length distribution data.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
91.
HYPOIMMUNOGENIC BETA CELLS AND METHODS OF PRODUCING THE SAME
Provided herein are methods and compositions for treating cancer or a tumor in a subject by administering to the subject T cells with reduced RGMb expression or activity and an immune checkpoint inhibitor such as a PD-1 or PD-L1 inhibitor.
Systems and methods related to microfluidic devices (e.g., microfluidic devices comprising layers of films) are generally described. In some embodiments, a microfluidic device comprises a substrate configured to facilitate fluid transport, one or more intermediate layers disposed on the substrate, wherein the one or more intermediate layers are configured to define a plurality of fluidly connected microfluidic components, and a top layer disposed on the one or more intermediate layers. In certain embodiments, a microfluidic device comprises a microfluidic channel having a gap or area of increased hydrophobicity in between two separated portions of the channel to separately pin one or more liquids in one or more desired portions of the channel. According to some embodiments, a microfluidic device comprises a microfluidic channel with an inclined surface, such that different portions of the microfluidic channel are associated with different channel heights.
222. The method is safe, scalable, and potentially inexpensive, as it utilizes non-volatile and potentially low-cost redox organic and inexpensive inorganic species and can operate at ambient temperature and pressure and can operate at high current densities.
B01D 53/14 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
B01D 53/32 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Devices, systems, and methods related to autonomous directional valves that allow fluids to stop and flow based on progressive changes in pressure are generally described.
Embodiments herein described provide antigen-presenting cell-mimetic scaffolds (APC-MS) and use of such scaffolds to manipulate T-cells. More specifically, the scaffolds are useful for promoting growth, division, differentiation, expansion, proliferation, activity, viability, exhaustion, anergy, quiescence, apoptosis, or death of T-cells in various settings, e.g., in vivo. In particular, the scaffolds are useful for enhancing the efficacy of an administered population of a engineered T-cells, such as CAR T-cells. Embodiments described herein further relate to pharmaceutical compositions, kits, and packages containing such scaffolds. Additional embodiments relate to methods for making the scaffolds, compositions, and kits/packages. Also described herein are methods for using the scaffolds, compositions, and/or kits in the treatment of diseases such as cancers.
Described herein are compositions and methods for downregulating the expression of Stromal Antigen 1 (STAG1). The compositions described comprise antisense oligonucleotides (ASOs) having sequences sufficiently complementary to a portion of a STAG1 primary transcript. Compositions comprising ASOs described can be used for the treatment of cancer, including cohesin-deficient cancers and STAG2-deficient cancers.
The development of new immunoregulatory small molecules represents a significant advance in immunotherapy. Provided herein are compounds, such as compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, and compositions, methods, uses, and kits that may be used in immunotherapy. The compounds provided herein are responsible for immunomodulatory signaling through the TLR2 receptor and are therefore useful for the treatment and/or prevention of various diseases (e.g., metabolic diseases, inflammatory diseases, immune disorders, or proliferative diseases).
A61K 31/688 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
100.
METHOD OF FORMING AN ALIGNED TISSUE OR TISSUE CONSTRUCT, A TISSUE OR TISSUE CONSTRUCT, AND BIOINK
Described herein is a method of forming an aligned tissue or tissue construct. The method includes extruding a bioink material through a nozzle onto a support to form a structure of the bioink material, the bioink material comprising anisotropic organ building blocks (aOBBs) comprising extracellular matrix material (ECM) and cellularly aligned cells, wherein the aOBBs align parallel to the direction of the extrude path, and polymerizing the structure of the bioink material, thereby forming the tissue or tissue construct having arbitrarily programmed alignment. Also, described is a tissue or tissue construct produced by the method, as well as bioink material used to produce the same.
patents
